Description of Research Expertise:
Dr. Briceño is interested in studying surgical and quality of life outcomes in eyelid, orbital and lacrimal surgery. He is also interested in finding ways to enhance medical student and resident education, especially in surgical settings. He is also interested in finding novel ways enhance provider diversity within the surgical subspecialties.
Thyroid eye disease, orbit, eyelid, ptosis, blepharoplasty, ectropion, entropion, trichiasis, nasolacrimal duct obstruction, orbital fracture, orbital tumors, tear duct problems, trauma, chalazion, filler, botox
Gupta S, Briceño CA, Nelson C, Douglas RS.: Customized Minimally Invasive Orbital Decompression for Thyroid Eye Disease. Expert Review of Ophthalmology. : 2012.
Briceño César A, Gupta Shivani, Douglas Raymond S: Advances in the management of thyroid eye disease. International ophthalmology clinics 53 (3): 93-101,2013.
Briceño César A, Zhang-Nunes Sandy X, Massry Guy G: Minimally invasive options for the brow and upper lid. Facial plastic surgery clinics of North America 23 (2): 153-66,2015.
Briceño César A, Zhang-Nunes Sandy X, Massry Guy G: Minimally invasive surgical adjuncts to upper blepharoplasty. Facial plastic surgery clinics of North America 23 (2): 137-51,2015.
Briceño CA, Massry GG: Chapter 10: Minimally Invasive Complementary Adjuncts to Upper Blepharoplasty. Master Techniques in Facial Rejuvenation, Second Edition : 107-119,2018.
Briceño César A, Elner Victor M, Demirci Hakan: Lymphangiogenic and Chemotactic Factors in Conjunctival Melanoma. Ophthalmic Plastic and Reconstructive Surgery 32 (6): 428-433,2016.
Ballard Tiffany N S, Briceño César A: Minocycline-induced orbital rim discoloration. Journal of AAPOS 20 (2): 182-4,2016.
Cani Andi K, Soliman Moaaz, Hovelson Daniel H, Liu Chia-Jen, McDaniel Andrew S, Haller Michaela J, Bratley Jarred V, Rahrig Samantha E, Li Qiang, Briceño César A, Tomlins Scott A, Rao Rajesh C: Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. Modern Pathology 29 (7): 685-697,2016.
View all publications